Humanigen

Humanigen is a clinical-stage biopharmaceutical company that was focused on developing a portfolio of proprietary immuno-oncology and immunomodulatory antibodies. The company's main goal was to create therapies for critical medical conditions, particularly by developing monoclonal antibodies to prevent and treat cytokine storms, a severe immune reaction that can occur in various cancers and infectious diseases, including COVID-19.

Its business model revolved around the research and development of these antibody therapeutics, with the aim of bringing them to market after successful clinical trials and regulatory approval. The company was publicly traded and sought to raise capital from investors to fund its extensive R&D activities. However, Humanigen faced significant challenges, primarily its struggle to gain regulatory approval for its COVID-19 treatment, which was a major focus. This setback, coupled with a failed reverse merger, led to severe financial distress. In early 2024, the company filed for Chapter 11 bankruptcy.

Keywords: biopharmaceutical, immuno-oncology, monoclonal antibodies, cytokine storm, clinical-stage, antibody therapeutics, infectious diseases, cancer treatment, bankruptcy, regulatory approval